Vancomycin trial for rare liver disease halted early
Disease control
Terminated
This study aimed to see if the antibiotic vancomycin could safely improve liver function in adults with primary sclerosing cholangitis (PSC), a rare liver disease. About 102 participants were planned to take vancomycin or a placebo for up to 24 months. The trial was terminated ea…
Phase: PHASE2, PHASE3 • Sponsor: Elizabeth Carey • Aim: Disease control
Last updated May 08, 2026 02:08 UTC